Navigation Links
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
Date:5/19/2009

of IPF-related deaths during treatment was also lower among patients treated with pirfenidone. IPF-related deaths occurred during the treatment period in 4.1% of patients in the pirfenidone group and 8.1% of patients in the placebo group in CAPACITY 1. IPF-related deaths occurred during the treatment period in 2.9% of pirfenidone group and 6.3% of patients in the placebo group in CAPACITY 2.

Treatment Discontinuation due to Adverse Events

Pirfenidone was safe and generally well tolerated. Relatively few adverse events resulted in treatment discontinuations. The percentage of patients in the 2403 mg pirfenidone and placebo groups across both CAPACITY studies who discontinued treatment (pirfenidone/placebo) due to various adverse events were as follows: IPF (2.9/2.6); rash (1.4/0); nausea (1.4/0); bladder cancer (0.9/0); photosensitivity reaction (0.9/0.3); respiratory failure (0.9/0.3) and weight decrease (0.6/0).

Laboratory Tests

A total of 30 laboratory tests were regularly performed in CAPACITY. The incidence of grade 3/4 laboratory abnormalities was similar between treatment groups in both studies. In six of the tests, Grade 3/4 abnormalities were noted slightly more frequently in patients treated with pirfenidone (phosphate elevation, hyponatremia, lymphopenia, ALT elevation, AST elevation and cholesterol elevation). Of these laboratory abnormalities in pirfenidone patients, all but one case each of hyponatremia and lymphopenia were Grade 3. In four of the laboratory tests, Grade 3/4 abnormalities were noted slightly more frequently in patients treated with placebo (urate elevation, hyperkalemia, amylase elevation and creatine kinase elevation). Both the incidence of grade 3/4 lab abnormalities and the differences observed between treatment groups on all tests were small.

Regarding the overall safety results, Dr. du Bois commented, "The safety and tolerabilit
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
4. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
5. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
6. AlphaVax Announces Promising Results in Melanoma Studies
7. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
8. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
9. Bionovo Announces First Quarter 2009 Highlights and Financial Results
10. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
11. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Advanced Photonix ® (NYSE MKT: API) will ... results on Monday, August 11, 2014. A press release announcing ... the market and the Company will host a live audio ... on the same day. Participating in the call ... Rob Risser (COO and Director), and Jeff Anderson ...
(Date:7/30/2014)... July 30, 2014  Unilife Corporation ("Unilife" or ... developer and supplier of injectable drug delivery systems, ... capacity, R&D, and facilities in response to increasing ... products and services. During the fourth quarter of ... million in capital expenditures and R&D above normal ...
(Date:7/30/2014)... 30, 2014 /PRNewswire-iReach/ -- Transluminal Technologies LLC, a ... company, has announced today that they have received ... Closure Device. Velox CD™ provides a safe and ... femoral procedures. The single size velox CD™ is ... from 5F to 8F.  Velox CD™ ...
Breaking Medicine Technology:Advanced Photonix to Webcast Fiscal 2015 First Quarter Earnings 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 4Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 5Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2
... Calif., March 7, 2012  Isis Pharmaceuticals, Inc. (NASDAQ: ... 1 study of ISIS-STAT3Rx, a Generation 2.5 antisense drug ... of signal transducer and activator of transcription 3 (STAT3). ... cancers, ISIS-STAT3Rx has the potential to be broadly useful ...
... March 7, 2012  Solta Medical, Inc. (NASDAQ: ... market, today provided an update on the launch of ... approved by the FDA. A majority ... comprised of leading plastic surgeons and dermatologists, who received ...
Cached Medicine Technology:Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx 2Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx 3Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx 4Solta Medical Provides Update on Liposonix Launch 2Solta Medical Provides Update on Liposonix Launch 3Solta Medical Provides Update on Liposonix Launch 4
(Date:7/31/2014)... (PRWEB) July 31, 2014 Cheerag ... experienced, sub-specialty trained neurosurgeons at the Saint Luke’s ... Spine Program and director of spine surgery. He comes ... Wash. , “Dr. Upadhyaya has been recognized for his ... complex spine issues. His addition to the Saint Luke’s ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 What’s ... practice provider? Community Health Center of Snohomish answers ... Pediatricians vs. Family Doctors ”. Many adults can ... available to them. Community Health Center hopes to ... and differences between the two. , To ...
(Date:7/31/2014)... Bellava MedAesthetics is proud to introduce ... surgeon! , Dr. Kim has more than a ... the look of their dreams. He focuses on natural ... augmentation (including Gummy Bear implants ), laser liposuction, ... Brazilian butt lift), abdominoplasty (tummy tuck), rhinoplasty, blepharoplasty (eyelid ...
(Date:7/31/2014)... 2014 When it comes to aesthetics ... and improve. As such, Natalie Sharp's Pure Vitality ... for a new, more focused direction and to provide ... patients! , Pure Vitality Rx is Oyster Bay's premier ... wide variety of services primarily dedicated to women. Services ...
(Date:7/31/2014)... Boston, MA (PRWEB) July 31, 2014 Many ... fight for the weak, to correct injustices, and preserve the ... - action that can be lauded as crusading and exemplary ... the lawyer takes on corruption whose seed might be planted ... a fury and the ultimate punishment for an attorney - ...
Breaking Medicine News(10 mins):Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 2Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 3Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 4Health News:Community Health Center of Snohomish County Reveals the Differences Between Pediatricians and Family Practice Providers 2Health News:Bellava MedAesthetics Welcomes Dr. Chang Soo Kim as Its New Westchester Plastic Surgeon 2Health News:Natalie Sharp's Pure Vitality Rx Upgrade - Partnership With Shangri-La Spa and Website Facelift! 2Health News:Supreme Court Press Petition of the Month for July 2014: Shutting Down Inconvenient Lawyers By Disbarment or Suspension 2Health News:Supreme Court Press Petition of the Month for July 2014: Shutting Down Inconvenient Lawyers By Disbarment or Suspension 3
... Carolina at Chapel Hill researchers published a study that found ... to have Parkinson,s disease than people with high LDL levels. ... whether low LDL (low-density lipoprotein) levels were present in study ... developed low LDL levels after being diagnosed. , Now a ...
... 4, 2008 Smart Balance,Inc. (Nasdaq: SMBL ) ... been named to the position of vice president, business,development. ... vice president,general manager, Midwest. Brett Meltzer has been named ... three are new employees of the,Company., "I am ...
... raises prospect of new treatment for tick-borne diseases in ... injection of a long-acting version of the antibiotic doxycycline ... Lyme disease or anaplasmosis, new animal research reveals. , ... raises hope for developing a safer and more effective ...
... & Research (NTMir), a,Miami, Florida based not-for-profit organization, ... been awarded to the Research,Institute of the McGill ... Genome Sequence of Mycobacterium avium intracellulare.", The ... NTMir in its innovative,research initiative, Rapid Information Pilot ...
... Business and,Disrupt Services to as Many as a Half ... April 4, 2008 A new Medicare,bidding program for ... Cincinnati and Cleveland, Ohio areas on July 1, 2008,will ... likely disrupt,services for many of the 540,000 seniors and ...
... A promising vaccine being tested for Alzheimer,s disease does ... plaques from the brain -- but it does not ... according to a University of California, Irvine study. , ... Alzheimer,s disease -- beta-amyloid plaques -- by itself may ...
Cached Medicine News:Health News:Pieces coming together in Parkinson's, cholesterol puzzle 2Health News:Smart Balance Announces Sales Organization Appointments 2Health News:Smart Balance Announces Sales Organization Appointments 3Health News:Injectable Antibiotic Protects Against Lyme Disease in Mice 2Health News:Injectable Antibiotic Protects Against Lyme Disease in Mice 3Health News:Errors Plague Medicare 'Competitive Bidding' Program in Ohio, Says American Association for Homecare 2Health News:Errors Plague Medicare 'Competitive Bidding' Program in Ohio, Says American Association for Homecare 3Health News:Errors Plague Medicare 'Competitive Bidding' Program in Ohio, Says American Association for Homecare 4Health News:Alzheimer's vaccine clears plaque but has little effect on learning and memory impairment 2
Printed with large 20/200 E on one side and a series of five 20/20 tumbling Es on the other- calibrated to a 20 ft. distance. May be used to test and train peripheral awareness....
... 2/25 is an economically priced 2-channel ... and research use in the fields ... neurophysiology, biology, zoology, biochemistry and biomedical ... ADInstruments signal conditioners and transducers. Two ...
... The PowerLab/4SP is a high-performance data ... of research applications including human and animal ... biomedical engineering. The unit is capable of ... speeds (up to 200 000 samples per ...
... Worth 4 Dot with 955R Red/Green ... the presence of binocular vision. Consists ... illuminated discs: two green, one red ... at any distance. Patient wears red/green ...
Medicine Products: